AIM ImmunoTech (AIM) News Today $0.12 -0.01 (-5.39%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$0.13 +0.01 (+4.13%) As of 03/28/2025 07:48 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period AIM ImmunoTech made ‘significant strides’ over course of 2024March 27 at 11:37 PM | markets.businessinsider.comEarnings Preview For AIM ImmunoTechMarch 27 at 1:34 PM | benzinga.comAIM ImmunoTech Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate UpdateMarch 27 at 8:33 AM | markets.businessinsider.comAIM ImmunoTech Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand ConferenceMarch 11, 2025 | globenewswire.comInsider Buying: AIM ImmunoTech Inc. (NYSE:AIM) CEO Acquires 83,334 Shares of StockMarch 5, 2025 | insidertrades.comAIM announces Paul Goepfert, MD, as the principal investigator for the planned clinical study of Ampligen and FluMist as a vaccine for avian influenzaFebruary 28, 2025 | globenewswire.comAIM ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing ComplianceFebruary 26, 2025 | globenewswire.comAIM ImmunoTech appoints Chemerow as an Independent DirectorFebruary 26, 2025 | msn.comAIM ImmunoTech Appoints David Chemerow to BoardFebruary 26, 2025 | tipranks.comAIM ImmunoTech Appoints David Chemerow to Board of Directors as an Independent DirectorFebruary 26, 2025 | globenewswire.comAIM ImmunoTech doses first subject in Phase 2 study of Ampligen, ImfinziFebruary 26, 2025 | markets.businessinsider.comAIM Doses First New Subject in Phase 2 Study of Ampligen and Imfinzi as a Potential Combination Therapy for Late-Stage Pancreatic CancerFebruary 25, 2025 | globenewswire.comAIM stock touches 52-week low at $0.13 amid market challengesFebruary 14, 2025 | msn.comAIM ImmunoTech to not proceed with offering pursuant to registration statementFebruary 11, 2025 | markets.businessinsider.comAIM ImmunoTech Releases Virtual Investor “What This Means Segment”February 11, 2025 | globenewswire.comAIM ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ended December 31, 2024February 11, 2025 | globenewswire.comAIM ImmunoTech announces follow-up clinical study of Ampligen with FluMistFebruary 8, 2025 | markets.businessinsider.comAIM ImmunoTech advances Ampligen for avian influenza vaccineFebruary 8, 2025 | msn.comAIM ImmunoTech announces a planned follow-up clinical study evaluating a combination treatment of AIM's Ampligen® and AstraZeneca's FluMist® to address the recent avian influenza outbreaksFebruary 7, 2025 | globenewswire.comAIM ImmunoTech announces Safety Committee approval to proceed with Phase 2February 5, 2025 | markets.businessinsider.comCornish Metals Inc ("Cornish Metals" or the "Company") (AIM/TSX-V: CUSN) Result of Retail OfferJanuary 31, 2025 | globenewswire.comCornish Metals Inc (AIM/TSX-V: CUSN) ("Cornish Metals" or the "Company") Result of FundraisingJanuary 28, 2025 | globenewswire.comAIM ImmunoTech files to sell units, no amount givenJanuary 23, 2025 | msn.comAIM ImmunoTech Announces Publication of Final Clinical Study Results for AMP-518 Clinical Trial on Ampligen as a Therapeutic for Post-COVID ConditionsJanuary 23, 2025 | globenewswire.comAIM ImmunoTech highlights new article on links between COVID-19, ME/CFSJanuary 22, 2025 | markets.businessinsider.comAIM ImmunoTech Highlights Higher Post-COVID Prevalence Of Myalgic Encephalomyelitis/Chronic FatigueJanuary 22, 2025 | markets.businessinsider.comAIM ImmunoTech Highlights New Article Finding Links Between COVID-19 and ME/CFSJanuary 22, 2025 | globenewswire.comAIM ImmunoTech highlights 2024 milestones achievedJanuary 16, 2025 | markets.businessinsider.comAIM ImmunoTech Highlights Key 2024 Achievements and Outlines Upcoming 2025-26 Value-Driving MilestonesJanuary 15, 2025 | globenewswire.comTed Kellner low-key on joining pharma firm board he fought to joinDecember 20, 2024 | bizjournals.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsDecember 18, 2024 | finanznachrichten.deAIM ImmunoTech receives noncompliance notification from NYSEDecember 18, 2024 | markets.businessinsider.comPharma company proxy fight ends in mixed results for Ted KellnerDecember 17, 2024 | bizjournals.comAIM ImmunoTech Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsDecember 17, 2024 | globenewswire.comAIM ImmunoTech Announces Election of Three Incumbent Board Members at Annual MeetingDecember 17, 2024 | businesswire.comTed Kellner's multimillion-dollar fight to unseat pharma firm's boardDecember 17, 2024 | bizjournals.comAIM ImmunoTech Reminds Shareholders to Vote "FOR" All Four Incumbent Board Members on the WHITE Universal Proxy CardDecember 16, 2024 | tmcnet.comKellner Group Denounces False Rumors About AIM Short Selling and Demands Immediate Accountability from Incumbent BoardDecember 14, 2024 | globenewswire.comAIM ImmunoTech gains Netherlands patent for post-Covid fatigue therapyDecember 13, 2024 | finance.yahoo.comAIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card "FOR" All Four Incumbent Board MembersDecember 12, 2024 | tmcnet.comAIM ImmunoTech Urges Shareholders to Vote on the WHITE Universal Proxy Card “FOR” All Four Incumbent Board MembersDecember 12, 2024 | businesswire.comAIM ImmunoTech Expands Patent Portfolio with New Netherlands Composition and Methods Patent Covering Ampligen for Use in the Post-COVID Condition of FatigueDecember 12, 2024 | globenewswire.comKellner Group Announces Support from Another Former AIM Senior ExecutiveDecember 12, 2024 | globenewswire.comAIM’s Clinical Strategy Under Incumbent Board Has Totally FailedDecember 11, 2024 | markets.businessinsider.comAIM's Clinical Strategy Under Incumbent Board Has Totally FailedDecember 11, 2024 | globenewswire.comGlass Lewis Recommends AIM ImmunoTech Shareholders Vote "FOR" Company Nominees Nancy K. Bryan, Thomas K. Equels and Dr. William M. MitchellDecember 10, 2024 | uk.finance.yahoo.comGlass Lewis Recommends AIM ImmunoTech Shareholders Vote “FOR” Company Nominees Nancy K. Bryan, Thomas K.December 10, 2024 | businesswire.comAmpligen Co-Inventor and Former CEO Agrees to Join AIM Scientific Advisory Board if Kellner Group Nominees Are ElectedDecember 10, 2024 | globenewswire.comAIM ImmunoTech Participates in Virtual Investor KOL Connect SegmentDecember 6, 2024 | globenewswire.comKellner Group Urges Stockholders of AIM Immunotech to Vote the Gold CardDecember 6, 2024 | globenewswire.com Remove Ads Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address AIM Media Mentions By Week AIM Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AIM News Sentiment▼0.000.81▲Average Medical News Sentiment AIM News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AIM Articles This Week▼32▲AIM Articles Average Week Remove Ads Get AIM ImmunoTech News Delivered to You Automatically Sign up to receive the latest news and ratings for AIM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies AKTX News BLUE News FGEN News ALXO News CVKD News OSTX News IRD News TPST News ESLA News RVPH News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:AIM) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThe Dirty Secret About Gold Mining Stocks...Here's something most gold analysts won't tell you: 90% of gold mining companies actually destroy sharehold...Golden Portfolio | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredWall Street’s “AI Oracle” Reveals Next Big Tech PlayA tiny American tech company could be at the center of the next big AI breakthrough. Wall Street's "AI Orac...InvestorPlace | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
